Schedule 13G ownership disclosure

Inhibikase Therapeutics Inc

Common Stock, $0.001 par value per share · CUSIP: 45719W205

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Sands Capital Life Sciences Pulse Fund II, L.P.

    Shares: 10,950,000.00 · Class: 14.7%

  • Sands Capital Alternatives, LLC

    Shares: 10,950,000.00 · Class: 14.7%

  • SANDS FRANK M.

    Shares: 10,950,000.00 · Class: 14.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001875620-25-000021
Form type
SCHEDULE 13G/A
Filer
Inhibikase Therapeutics, Inc.
CIK
CIK 1750149
Filed
Aug 13, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub